With the emergence of a new generation of drugs (e.g. sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRAs)) ground breaking impulses were given to the therapy of DKD, supported by studies showing a reduced incidence of combined renal endpoints with acceptable safety profiles [6]. The gene discussed is NR3C2; the disease is diabetic kidney disease.